AU2001277961A1 - Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof - Google Patents
Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereofInfo
- Publication number
- AU2001277961A1 AU2001277961A1 AU2001277961A AU7796101A AU2001277961A1 AU 2001277961 A1 AU2001277961 A1 AU 2001277961A1 AU 2001277961 A AU2001277961 A AU 2001277961A AU 7796101 A AU7796101 A AU 7796101A AU 2001277961 A1 AU2001277961 A1 AU 2001277961A1
- Authority
- AU
- Australia
- Prior art keywords
- macroglobulin
- saponins
- alpha
- compositions
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22313300P | 2000-08-07 | 2000-08-07 | |
US60223133 | 2000-08-07 | ||
PCT/US2001/023098 WO2002011669A2 (en) | 2000-08-07 | 2001-07-20 | Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001277961A1 true AU2001277961A1 (en) | 2002-02-18 |
Family
ID=22835177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001277961A Abandoned AU2001277961A1 (en) | 2000-08-07 | 2001-07-20 | Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof |
Country Status (3)
Country | Link |
---|---|
US (1) | US20020037290A1 (en) |
AU (1) | AU2001277961A1 (en) |
WO (1) | WO2002011669A2 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
AU6669401A (en) | 2000-06-02 | 2001-12-11 | Univ Connecticut Health Ct | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
IT1319277B1 (en) * | 2000-10-24 | 2003-09-26 | Chiesi Farma Spa | MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT. |
US20030138434A1 (en) * | 2001-08-13 | 2003-07-24 | Campbell Robert L. | Agents for enhancing the immune response |
JP4384489B2 (en) * | 2001-08-20 | 2009-12-16 | ユニバーシティー オブ コネティカット ヘルス センター | Method for preparing a composition comprising a heat shock protein or α-2-macroglobulin useful for the treatment of cancer and infectious diseases |
EP1572894B1 (en) * | 2001-11-21 | 2016-04-13 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto |
AU2003213700A1 (en) * | 2002-03-01 | 2003-09-16 | Applied Immune Technologies | Immunogens for treatment of neoplastic and infectious disease |
WO2003090686A2 (en) | 2002-04-25 | 2003-11-06 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
US6984389B2 (en) * | 2002-04-25 | 2006-01-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
US7722595B2 (en) | 2002-05-06 | 2010-05-25 | Becton, Dickinson And Company | Method and device for controlling drug pharmacokinetics |
AU2003303198A1 (en) | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
JP2006514088A (en) * | 2003-02-20 | 2006-04-27 | ユニバーシティー オブ コネティカット ヘルス センター | Use of a composition comprising heat shock protein or α-2-macroglobulin in the treatment of cancer and infectious diseases |
EP1625141A4 (en) * | 2003-05-12 | 2007-07-04 | Philadelphia Children Hospital | Grp94-based compositions and methods of use thereof |
CN1310650C (en) * | 2003-07-16 | 2007-04-18 | 中国科学院上海药物研究所 | Application of saponins in the preparing process of coxsackie virus resisting medicine |
BRPI0603490B1 (en) * | 2006-07-21 | 2018-04-24 | Universidade Federal De Minas Gerais | RECOMBINING VACCINE AGAINST CANCER VISCERAL LEISHMANIASIS |
US9012439B2 (en) * | 2007-10-29 | 2015-04-21 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
US9345753B2 (en) * | 2008-01-16 | 2016-05-24 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Vaccine for alzheimer's disease |
PL2659904T3 (en) | 2008-06-26 | 2016-01-29 | Orphazyme Aps | Use of Hsp70 as a regulator of enzymatic activity |
PL2646044T3 (en) | 2010-11-30 | 2020-03-31 | Orphazyme A/S | Methods for increasing intracellular activity of hsp70 |
WO2013013056A1 (en) | 2011-07-19 | 2013-01-24 | New York University | Method for treating amyloid disease |
WO2013012811A2 (en) | 2011-07-19 | 2013-01-24 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
AU2013222414B2 (en) | 2012-02-21 | 2018-02-15 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
WO2015017280A1 (en) * | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
CN106163540A (en) * | 2013-09-13 | 2016-11-23 | 安达卢西亚进步与健康公共基金会 | For treating albumen disease or the collectin of conformational disease and the combination of molecular chaperones |
WO2016041561A1 (en) | 2014-09-15 | 2016-03-24 | Orphazyme Aps | Arimoclomol formulation |
EP3442530A1 (en) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
ES2831764T3 (en) | 2016-04-29 | 2021-06-09 | Orphazyme As | Arimoclomol for the treatment of glucocerebrosidase-associated disorders |
US20180328943A1 (en) * | 2016-09-30 | 2018-11-15 | Enzo Biochem, Inc. | Immunomodulatory compositions and methods of use thereof |
KR20230128462A (en) | 2020-11-19 | 2023-09-05 | 제브라 덴마크 에이/에스 | Process for preparing arimoclomol citrate and intermediates thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5273965A (en) * | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
-
2001
- 2001-07-20 WO PCT/US2001/023098 patent/WO2002011669A2/en active Application Filing
- 2001-07-20 US US09/909,778 patent/US20020037290A1/en not_active Abandoned
- 2001-07-20 AU AU2001277961A patent/AU2001277961A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002011669A2 (en) | 2002-02-14 |
US20020037290A1 (en) | 2002-03-28 |
WO2002011669A3 (en) | 2002-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001277961A1 (en) | Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof | |
AU2002230831A1 (en) | Compositions of human proteins and method of use thereof | |
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
AU2001255196A1 (en) | Compositions and methods for enhancing immunogenicity of antigens | |
AU2001267475A1 (en) | Combinations of Enzyme Inhibitor-Containing Preparations and the use thereof | |
HUP0101804A3 (en) | Adjuvant composition and methods for its use | |
AU2002224079A1 (en) | O/W emulsion composition and method of preparing the same | |
AU6669401A (en) | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy | |
IL150219A0 (en) | Mulch composition and methods for the preparation and use thereof | |
AU2002220460A1 (en) | The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits | |
EP1150701A4 (en) | Homing pro-apoptotic conjugates and methods of using same | |
AU5577201A (en) | Immunogenic pneumococcal protein and vaccine compositions thereof | |
AU2001292667A1 (en) | Immunogenic composition of hepatitis c and methods of use thereof | |
AUPQ712000A0 (en) | Antigenic peptide fragments of VapA protein, and uses thereof | |
AU2001269730A1 (en) | Low carbohydrate compositions, kits thereof, and methods of use | |
AU2756301A (en) | Compositions comprising genome segments and methods of using the same | |
EP1435996A4 (en) | Compositions comprising mixtures of therapeutic proteins and methods of producing the same | |
AU3755999A (en) | Proteins that direct the secretion of virulence proteins and vaccines comprisingthem | |
WO2002077233A8 (en) | 38650, 28472, 5495, 65507, 81588 and 14354 METHODS AND COMPOSITIONS OF HUMAN PROTEINS AND USES THEREOF | |
AU2002343042A8 (en) | Virulence proteins of the genus yersinia and uses thereof | |
AU2001234616A1 (en) | Vaccine composition, process and methods | |
AU2001271281A1 (en) | Novel compositions for the expression of the human peptide histidine transporter1 and methods of use thereof | |
AU2001297794A1 (en) | Methods and compositions of human proteins and uses thereof. | |
AU2002245158A1 (en) | Human proteins 55562 and 21617, and methods of use thereof | |
AU2002214598A1 (en) | Claspin proteins and methods of use thereof |